Jordan A. Shavit

Jordan A. Shavit

Auto-generated profile, based on publicly available information

Jordan A. Shavit

University of Michigan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JNJonas B. Nielsen
Jonas B. Nielsen
RTRosa B. Thorolfsdottir
Rosa B. Thorolfsdottir
LFLars G. Fritsche
Lars G. Fritsche
WZWei Zhou
Wei Zhou
MSMorten W. Skov
Morten W. Skov
CWCristen J. Willer
Cristen J. Willer

30 January 2020 in JCI Insight
Verified
Journal Article
Closed access
PDF file
AHAdam S. Helms
Adam S. Helms
VTVi T. Tang
Vi T. Tang
TOThomas S O'Leary
Thomas S O'Leary
SFSabrina Friedline
Sabrina Friedline
MWMick Wauchope
Mick Wauchope
SDSharlene M. Day
Sharlene M. Day
Mutations in cardiac myosin binding protein C (MyBP-C, encoded by MYBPC3 ) are the most common cause of hypertrophic cardiomyopathy (HCM). Most MYBPC3 mutations result in premature termination codons (PTCs) that cause RNA degradation and a reduction of MyBP-C in HCM patient hearts. However, a reduction in MyBP-C has not been consistently observed in MYBPC3 -mutant induced pluripotent stem cell cardiomyocytes (iPSCMs). To determine early MYBPC3 mutation effects, we used patient and genome-engineered iPSCMs. iPSCMs with frameshift mutations were compared with iPSCMs with MYBPC3 promoter and translational start site deletions, revealing that allelic loss of function is the primary inciting consequence of mutations causing PTCs. Despite a reduction in wild-type mRNA in all heterozygous iPSCMs, no reduction in MyBP-C protein was observed, indicating protein-level compensation through what we believe is a previously uncharacterized mechanism. Although homozygous mutant iPSCMs exhibited contractile dysregulation, heterozygous mutant iPSCMs had normal contractile function in the context of compensated MyBP-C levels. Agnostic RNA-Seq analysis revealed differential expression in genes involved in protein folding as the only dysregulated gene set. To determine how MYBPC3 -mutant iPSCMs achieve compensated MyBP-C levels, sarcomeric protein synthesis and degradation were measured with stable isotope labeling. Heterozygous mutant iPSCMs showed reduced MyBP-C synthesis rates but a slower rate of MyBP-C degradation. These findings indicate that cardiomyocytes have an innate capacity to attain normal MyBP-C stoichiometry despite MYBPC3 allelic loss of function due to truncating mutations. Modulating MyBP-C degradation to maintain MyBP-C protein levels may be a novel treatment approach upstream of contractile dysfunction for HCM.

1 September 2014 in Current Opinion in Hematology
Verified
Journal Article
Closed access
AWAngela C. Weyand
Angela C. Weyand
JSJordan A. Shavit
Jordan A. Shavit
Purpose of review Although the zebrafish has been established as a research tool over the past two to three decades, in hematology it has primarily been used to investigate areas distinct from coagulation. The advantages of this vertebrate model include high fecundity, rapid and external development, and conservation of virtually all clotting factors in the zebrafish genomic sequence. Here, we summarize the growing application of this technology to the study of hemostasis and thrombosis. Recent findings Loss of function studies have demonstrated conservation of function for a number of zebrafish coagulation factors. These include positive and negative regulators of coagulation, as well as key components of the thrombus itself, such as von Willebrand factor, fibrinogen, and thrombocytes. Such analyses have also been leveraged to aid in the understanding of human variation and disease, as well as to perform in-vivo structure/function experiments. Summary The zebrafish is an organism that lends itself to a number of unique and powerful approaches not possible in mammals. This review demonstrates that there is a high degree of genetic and functional conservation of coagulation, portending future insights into hemostasis and thrombosis through the use of this model.

3 July 2014 in Blood
Verified
Journal Article
Open access
PDF file
YLYang Liu
Yang Liu
CKColin A. Kretz
Colin A. Kretz
MMMorgan L. Maeder
Morgan L. Maeder
CRCatherine E. Richter
Catherine E. Richter
PTPhilip Tsao
Philip Tsao
JSJordan A. Shavit
Jordan A. Shavit
Key Points: Juvenile zebrafish tolerate widespread coagulopathy due to complete ablation of antithrombin III, but develop lethal thrombosis as adults. In vivo structure/function analysis of antithrombin III in zebrafish reveals limited roles for heparin-binding and anti-IXa/Xa activity.

30 September 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AVAndy H. Vo
Andy H. Vo
ASAlok Swaroop
Alok Swaroop
YLYang Liu
Yang Liu
ZNZachary G. Norris
Zachary G. Norris
JSJordan A. Shavit
Jordan A. Shavit
Cessation of bleeding after trauma is a necessary evolutionary vertebrate adaption for survival. One of the major pathways regulating response to hemorrhage is the coagulation cascade, which ends with the cleavage of fibrinogen to form a stable clot. Patients with low or absent fibrinogen are at risk for bleeding. While much detailed information is known about fibrinogen regulation and function through studies of humans and mammalian models, bleeding risk in patients cannot always be accurately predicted purely based on fibrinogen levels, suggesting an influence of modifying factors and a need for additional genetic models. The zebrafish has orthologs to the three components of fibrinogen (fga, fgb, and fgg), but it hasn’t yet been shown that zebrafish fibrinogen functions to prevent bleeding in vivo. Here we show that zebrafish fibrinogen is incorporated into an induced thrombus, and deficiency results in hemorrhage. An Fgb-eGFP fusion protein is incorporated into a developing thrombus induced by laser injury, but causes bleeding in adult transgenic fish. Antisense morpholino knockdown results in intracranial and intramuscular hemorrhage at 3 days post fertilization. The observed phenotypes are consistent with symptoms exhibited by patients with hypo- and afibrinogenemia. These data demonstrate that zebrafish possess highly conserved orthologs of the fibrinogen chains, which function similarly to mammals through the formation of a fibrin clot.

4 April 2015 in Current Pathobiology Reports
Verified
Journal Article
Closed access
PDF file
CKColin A. Kretz
Colin A. Kretz
AWAngela C. Weyand
Angela C. Weyand
JSJordan A. Shavit
Jordan A. Shavit